[Effect of thyroliberin on the clinical manifestations of the alcoholic abstinence syndrome].
In a double blind diagnostic study of the reserve thyrotropic function of the hypophysis, the authors have investigated the effect of the thyrotropic releasing hormone (TRH) versus placebo on the clinical manifestations of the alcohol abstinence syndrome in 60 patients with stage 2 chronic alcoholism. TRH and placebo-reactive and resistant symptoms of abstinence have been identified. TRH has a positive effect on some psychopathological and somatovegetative manifestations of alcohol abstinence. It is suggested that the use of TRH, in addition to its therapeutic and diagnostic value, will help to better study-at the clinical level-the role of the peptidergic system in the pathogenesis of alcohol-induced disorders.
D000328:Adult; D002986:Clinical Trials as Topic; D000431:Ethanol / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010903:Pituitary Gland, Anterior / Q000503:physiopathology*; D013375:Substance Withdrawal Syndrome / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D013972:Thyrotropin / Q000097:blood / Q000378:metabolism*; D013973:Thyrotropin-Releasing Hormone / Q000627:therapeutic use
D000431:Ethanol; D013973:Thyrotropin-Releasing Hormone; D013972:Thyrotropin
Izuchenie vliianiia tiroliberina na klinicheskie proiavleniia alkogol'nogo abstinentnogo sindroma.